NCT06584097 is a clinical trial in Neurosurgical Patients, sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta.

Who is sponsoring NCT06584097?

NCT06584097 is sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta.

What condition does NCT06584097 study?

NCT06584097 studies Neurosurgical Patients.

Is NCT06584097 still recruiting?

NCT06584097 is currently recruiting now. Last updated 12 February 2026.

Last reviewed 2026-02-12 · How we verify

NCT06584097

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COMparative Performance of General Purpose Models

Recruiting now Last updated 12 February 2026

What this trial tests

trial in Neurosurgical Patients in 42 participants. Currently enrolling.

Timeline

2 October 2024

Primary endpoint
1 October 2026

31 December 2026

Quick facts

Lead sponsor	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	42
Start date	2 October 2024
Primary completion	1 October 2026
Estimated completion	31 December 2026
Sites	2 locations across Italy

Conditions studied

Neurosurgical Patients — all drugs for Neurosurgical Patients →

Sponsor

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta — full company profile →

Who can join

Eligibility, any sex, with Neurosurgical Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the performance of the Eleveld models for propofol and remifentanil on neurosurgery patients admitted to intensive care with their intraoperative performance.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta trials

Trials by the same sponsor.

NCT07168850 — Focused Ultrasound Unilateral Pallidotomy for Medication-Refractory Limb Dystonia · NA · recruiting
NCT06699095 — Home Rehabilitation As Continuity of Care in MS · NA · recruiting
NCT06933212 — Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy. · recruiting
NCT07427940 — Omic Profile in Autism Spectrum Disorder: From Cellular Level Towards Future Treatments · NA · recruiting
NCT06844838 — FASt Track in Elective Neurosurgery: the Role of Low Propofol Bis-NOL Guided General Anaesthesia for Full, Early and Saf · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06584097 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Last refreshed: 12 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06584097.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing